Replies to post #434685 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761269s000lbl.pdf

Since the Lecanamab surrogate biomarker that gained AA was simply reduction in amyloid plaque, there isn’t any labelling subgroups similar to those predefined for analysis in the Anavex P2b/3 trial.

Imo it is very likely that the best and clinically meaningful response results for A2-73 will be in relatively narrow subgroups as we also saw in the P2a trial.